CD40–TNF receptor-associated factor 6 protein–protein interface (CD40–TRAF6 PPI)

The CD40–TNF receptor-associated factor 6 (TRAF6) protein–protein interface is a specialized signaling junction essential for mediating pro-inflammatory responses in various immune and vascular cells (Lutgens et al., 2010, Nature Medicine). CD40, a member of the tumor necrosis factor receptor superfamily, lacks intrinsic enzymatic activity and relies on the recruitment of adapter proteins like TRAF6 to its cytoplasmic domain to initiate signal transduction (UniProt P25942, Q9Y4K3). This interaction is particularly vital for the activation of the canonical NF-κB and MAPK pathways, which drive the production of cytokines, chemokines, and adhesion molecules. Pathologically, the CD40–TRAF6 axis is a key contributor to the progression of atherosclerosis, where it promotes plaque inflammation and instability, as well as in autoimmune disorders and certain malignancies (Seijkens et al., 2018, Cardiovascular Research). Therapeutic targeting of this interface using small molecule inhibitors or peptidomimetics aims to selectively block the pro-inflammatory arm of CD40 signaling without interfering with other CD40-TRAF interactions. This approach potentially avoids the systemic side effects and thromboembolic risks associated with global CD40 or CD40L inhibition, which previously hindered clinical development. Experimental compounds like 6877002 have demonstrated efficacy in reducing atherosclerotic plaque formation in animal models by specifically disrupting this protein-protein interaction.

Other names

CD40-TRAF6 interactionCD40-TRAF6 signaling axisCD40-TRAF6 complexCD40-TRAF6 signaling interface

Inhibition of the physical interaction between the CD40 cytoplasmic tail and the TRAF6 adapter protein to block downstream pro-inflammatory signaling pathways such as NF-κB and MAPK.